statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Biora Therapeutics announces interim results of BT-600 clinical trial

Mean Plasma Tofacitinib Concentration

 Following administration of a single oral dose of 5 mg and 10 mg BT-600

All pharmacokinetic endpoints were achieved, with a PK profile...

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap  Platform Development

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously...

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Biora Therapeutics announces $6M registered direct offering and concurrent private placement...

Biora Therapeutics announces $6M registered direct offering and concurrent private placement

Biora Therapeutics prices 5.45M shares at $1.10 in registered direct offering

SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into...

Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Biora Therapeutics (NASDAQ:BIOR  Get Free Report) and DURECT (NASDAQ:DRRX  Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the...

Head-To-Head Comparison: Biora Therapeutics (NASDAQ:BIOR) vs. DURECT (NASDAQ:DRRX)

Q4 2023 Biora Therapeutics Inc Earnings Call Transcript

All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower...

Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Earnings Outlook For Biora Therapeutics

Biora Therapeutics, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. Its products include the Preparent Carrier Test, Innatal Prenatal Screen, Riscover Hereditary Cancer Test, and Resura Prenatal Test. The company was founded by Paul W. Hawran and Harry Stylli in 2010 and is headquartered in San Diego, CA.

Volume	100.00
52-Wk High	$6.70
52-Wk Low	$0.585

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.45	--	--	N/A
Q4'23	-$0.60	--	--	N/A
Q3'23	-$0.93	-$4.89	-428.65%	MISSED
Q2'23	-$1.60	-$1.47	8.13%	BEAT
Q1'23	--	-$1.59	--	N/A

BIOR Biora Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals